Treatment of advanced neuroblastoma with I-131 meta-Iodobenzylguanide

A. Garaventa, P. Guerra, A. Arrighini, L. Bertolazzi, M. Bestagno, B. De Bernardi, E. Lanino, G. P. Villavecchia, F. Claudiani

Research output: Contribution to journalArticlepeer-review

Abstract

From February 1986 to December 1988, 31 children with advanced pretreated neuroblastoma were treated with 131-I-meta-Iodobenzylguanidine (131-MIBG). Thirteen children had been resistant to first-line therapy, three had sufiered a local relapse, and fourteen had suffered a disseminated relapse without overt bone marrow infiltration. One child was treated initially because of resistance to firstline therapy, and subsequently for a local relapse. A total of 72 courses of 131-MIBG was administered' with doses ranging from 2.8 to 6.0 GBq (median, 3.7 GB,). One child received five courses, two four courses, 13 three courses. four two courses, and 12 one courseof 131-MIBG. The most common toxic effect was thrombocytopenia, with a platelet level of less than 50,000/cmm occurring after 19 of 60 evaluable courses. A leukocyte count less than 1000/cmm was seen only once. There were six major responses (two complete) lasting 4 to 9 months, and two minor responses lasting longer than 38 and 44 months. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated who experienced disseminated relapse. Further studies of the role of 131-I-meta-Iodobenzylguanidine in treatment of neuroblastoma are needed.

Original languageEnglish
Pages (from-to)922-928
Number of pages7
JournalCancer
Volume67
Issue number4
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Treatment of advanced neuroblastoma with I-131 meta-Iodobenzylguanide'. Together they form a unique fingerprint.

Cite this